489 related articles for article (PubMed ID: 29924853)
41. Stereopsis after Intravitreal Ranibizumab Injections for Branch Retinal Vein Occlusion.
Morikawa S; Okamoto F; Sugiura Y; Murakami T; Hiraoka T; Oshika T
Ophthalmol Retina; 2019 Sep; 3(9):777-783. PubMed ID: 31155472
[TBL] [Abstract][Full Text] [Related]
42. Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab.
Sophie R; Wang PW; Channa R; Quezada-Ruiz C; Clark A; Campochiaro PA
Ophthalmology; 2019 Dec; 126(12):1695-1702. PubMed ID: 31543350
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
Campochiaro PA; Sophie R; Pearlman J; Brown DM; Boyer DS; Heier JS; Marcus DM; Feiner L; Patel A;
Ophthalmology; 2014 Jan; 121(1):209-219. PubMed ID: 24112944
[TBL] [Abstract][Full Text] [Related]
44. Predictors of As-Needed Ranibizumab Injection Frequency in Patients With Macular Edema Following Retinal Vein Occlusion.
Yiu G; Huang D; Wang Y; Wang Z; Yang M; Haskova Z
Am J Ophthalmol; 2023 May; 249():74-81. PubMed ID: 36646240
[TBL] [Abstract][Full Text] [Related]
45. Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion.
Hasegawa T; Murakawa S; Maruko I; Kogure-Katakura A; Iida T
Br J Ophthalmol; 2019 Jan; 103(1):72-77. PubMed ID: 29545416
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
Son BK; Kwak HW; Kim ES; Yu SY
Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
[TBL] [Abstract][Full Text] [Related]
47. Branch Retinal Vein Occlusion: Treatment Outcomes According to the Retinal Nonperfusion Area, Clinical Subtype, and Crossing Pattern.
Iida-Miwa Y; Muraoka Y; Iida Y; Ooto S; Murakami T; Suzuma K; Tsujikawa A
Sci Rep; 2019 Apr; 9(1):6569. PubMed ID: 31024035
[TBL] [Abstract][Full Text] [Related]
48. Ranibizumab for Macular Edema Secondary to Central and Branch Retinal Vein Occlusion in Patients Younger Than 50 Years of Age.
Battaglia Parodi M; Romano F; Arrigo A; Mercuri S; Franceschi A; Bandello F
Biomed Res Int; 2020; 2020():4747696. PubMed ID: 32685489
[TBL] [Abstract][Full Text] [Related]
49. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
50. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
Li F; Sun M; Guo J; Ma A; Zhao B
Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
[TBL] [Abstract][Full Text] [Related]
51. Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept.
Zhang Q; Hou Y; Cao X; Zhang R; Liu Y; Wei C; Wu C; Mei L; Zhang P
BMC Ophthalmol; 2021 Nov; 21(1):402. PubMed ID: 34809591
[TBL] [Abstract][Full Text] [Related]
52. Optical Coherence Tomography Biomarkers Predicting Visual Acuity Change after Intravitreal Bevacizumab Injections for Macular Edema Secondary to Branch Retinal Vein Occlusion.
Segal O; Yavnieli R; Mimouni M; Rabina G; Geffen N; Moisseiev E; Nemet AY
Ophthalmologica; 2022; 245(1):19-24. PubMed ID: 34510041
[TBL] [Abstract][Full Text] [Related]
53. BETTER PROGNOSIS FOR EYES WITH PRESERVED FOVEAL DEPRESSION AFTER INTRAVITREAL RANIBIZUMAB INJECTION FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Kitagawa S; Yasuda S; Ito Y; Ueno S; Iwase T; Terasaki H
Retina; 2018 Jul; 38(7):1354-1360. PubMed ID: 28538263
[TBL] [Abstract][Full Text] [Related]
54. Neuroretinal atrophy following resolution of macular oedema in retinal vein occlusion.
Podkowinski D; Philip AM; Vogl WD; Gamper J; Bogunovic H; Gerendas BS; Haj Najeeb B; Waldstein SM; Schmidt-Erfurth U
Br J Ophthalmol; 2019 Jan; 103(1):36-42. PubMed ID: 29511062
[TBL] [Abstract][Full Text] [Related]
55. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
[TBL] [Abstract][Full Text] [Related]
56. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion.
Wolf-Schnurrbusch UE; Ghanem R; Rothenbuehler SP; Enzmann V; Framme C; Wolf S
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3334-7. PubMed ID: 21087958
[TBL] [Abstract][Full Text] [Related]
57. Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion:
Pielen A; Feltgen N; Hattenbach LO; Hoerauf H; Bertelmann T; Quiering C; Vögeler J; Priglinger S; Lang GE; Schmitz-Valckenberg S; Wolf A; Rehak M
Curr Eye Res; 2020 May; 45(5):604-614. PubMed ID: 31665935
[No Abstract] [Full Text] [Related]
58. EVALUATION OF MACULAR ISCHEMIA IN EYES WITH CENTRAL RETINAL VEIN OCCLUSION: An Optical Coherence Tomography Angiography Study.
Ghashut R; Muraoka Y; Ooto S; Iida Y; Miwa Y; Suzuma K; Murakami T; Kadomoto S; Tsujikawa A; Yoshimura N
Retina; 2018 Aug; 38(8):1571-1580. PubMed ID: 28671896
[TBL] [Abstract][Full Text] [Related]
59. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
[TBL] [Abstract][Full Text] [Related]
60. [Does OCT morphology provide indications for prognosis of visual acuity after venous occlusion? : SD-OCT analysis in retinal vein occlusion before and after resolution of initial macular edema].
Schröder K; Ackermann P; Brachert M; Bairov S; Geerling G; Guthoff R
Ophthalmologe; 2016 Jun; 113(6):500-6. PubMed ID: 26939693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
